Abstract library

41 results for "Caff".
#67 Interest of combined chromogranin A and pancreatic polypeptide for diagnosis and follow-up of gastroenteropancreatic endocrine carcinoma
Introduction: Assessment of tumor burden changes is essential for the management of well-differentiated gastroenteropancreatic neuroendocrine carcinoma (GEPNET). Chromogranin A (CgA) is the principal tumor marker for such tumors; however, its use to evaluate morphological tumor progression is not validated. Combined CgA and pancreatic polypeptide (PP) may increase sensitivity in the diagnosis of GEP-NET.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Dr Thomas WALTER
#274 An Unexpected Diagnosis
Introduction: Paragangliomas (PGL) are defined as rare tumors arising from extra-adrenal sympathetic and parasympathetic paraganglia and malignant paragangliomas are defined by the presence of metastases.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr.ssa Chiara Martini
#918 Hyperinsulinemic Hypoglycemia by an Ovarian Germ Cell Tumor
Introduction: A 76-yr-old woman was admitted to our department for recurrent hot flushes, sweating and dizziness associated with fasting hypoglycemia. Physical examination revealed abdominal obesity and ascites.
Conference: 11th Annual ENETS Conference (2014)
Category: Clinical cases/reports
Presenting Author: Marialberta Battocchio
Keywords: ovary, insulin, SSA, everolimus
#958 Hypoglycemic Syndrome Recurrence after Surgical Removal of a Pancreatic Neuroendocrine Adenoma
Introduction: A 56-year-old woman was submitted to caudal pancreatectomy for an insulin-secreting adenoma suspected by MRI and fast test positivity at 38th hour. Intraoperative US excluded other pancreatic lesions but tissue analysis described a 8mm neuroendocrine well-differentiated tumor and the surrounding pancreatic tissue exhibited characteristics of nesidioblastosis. Five months after surgery, she still reported episodes of hypoglycemia requiring diazoxide therapy and she was admitted to our department.
Conference: 11th Annual ENETS Conference (2014)
Category: Clinical cases/reports
Presenting Author: MD Eugenio De Carlo
#968 An Early Rare MEN1 Phenotype
Introduction: A 13-yr-old boy was referred to our department for short stature.
Conference: 11th Annual ENETS Conference (2014)
Category: Clinical cases/reports
Presenting Author: Marialberta Battocchio
Keywords: MEN1, hypercorticism
#1301 Role of TSC22D1 (TGFβ-Stimulated Clone 22 Domain Family Member 1) in Bronchial Carcinoids
Introduction: Neuroendocrine tumors (NETs) include bronchial carcinoids, either typical (TC) or atypical (AC). Tsc22d1 encodes for a member of TSC22 domain family of leucine zipper transcription factors; the protein (TSC22D1) is stimulated by TGFβ. Microarray data analysis obtained comparing a pool of TC tissue specimens with a pool of AC tissue specimens shows TSC22D1 down-regulation in AC samples. These data were confirmed by real time PCR and Western blot in vitro models of TC (NCI-H727 cells) and AC (NCI-H720 cells)
Conference: 13th Annual ENETS conference (2016)
Category: Biomarkers
Presenting Author: PhD student Simona Falletta
#1581 Evaluation of Somatostatin and Dopamine Receptor Subtype 2 Expression in Pancreatic Neuroendocrine Neoplasms
Introduction: Although somatostatin receptor subtype 2 (SSTR2) and dopamine type 2 receptor (D2R) are reported to be expressed in neuroendocrine neoplasms (NEN), there is a lack of data from studies on a large number of patients with pancreatic NEN.
Conference: 14th Annual ENETS conference (2017)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Lingaku Lee
Authors: Lee L, Ito T, Kawabe K, Otsuka T, ...
#2257 Poorly Differentiated Neuroendocrine Carcinomas of the Colon: A Clinicopathological Study
Introduction: Neuroendocrine carcinomas (NEC) of the colon and rectum are aggressive and rare tumours. The Digestive Tract WHO classification 2010 defines the entity of large cell NEC (LCNEC) in contrast to small cell NEC (SCNEC).
Conference: 15th Annual ENETS conference (2018)
Category: Pathology - grading, staging
Presenting Author: Inga Boeck
Authors: Boeck I, Weihe E, Krieg A, Gabbert H E, ...
#18 Long-acting release octreotide induce complete response in type 1 gastric carcinoid tumors
Introduction: Gastric endocrine tumors (GET) are increasingly recognized due to expanding indications of upper gastrointestinal endoscopy. Often silent and benign, GET may also be aggressive when sporadic and may sometimes mimic the course of gastric adenocarcinoma. Current incidence of GETs is estimated at around 8% of digestive endocrine tumors. Yearly age-adjusted incidence is around 0.2 per population of 100,000. Gastric carcinoids (ECLomas) develop from gastric enterochromaffin-like cells (ECL cells) in response to chronically elevated gastrin. Type 1 tumors (ECLomas in the course of atrophic gastritis) may occur in conditions of achlorhydria secondary to auto-immune atrophic fundic gastritis. It occurs mostly in women and they are non-functioning tumors, typically found during upper GI endoscopy performed for dyspepsia. ECLomas present frequently as multiple polyps, usually < 1 cm in diameter in the gastric fundus. Type 1 tumors are almost exclusively benign lesions with little risk of deep invasion of the gastric parietal wall. The neoplastic ECL cells become progressively dedifferentiated with an increasing number of Ki-67 immunoreactive (IR) cell nuclei. In addition, there is a substantial decrease in argynophil and IR NE cells that can be visualized by conventional methods. ECLomas secondary to hypergastrinemia should be closely followed for signs of clinical and histopathological tumor progression. Such ECLomas deserve early, active, radical surgical treatment.
Traditionally, gastric carcinoid type 1 (GCA1s) are endoscopically or surgically removed, depending on the number, appearance and size of the tumors. Antrectomy, with surgical excision of the majority of the G cells, is thought to facilitate regression of these tumors by removing the source of excessive gastrin secretion; however, the long-term benefits of antrectomy still remain uncertain. Although proton pump inhibitors are effective in reducing hypergastrinemia-induced gastric acid hypersecretion in GCA2, they do not affect ECL-cell hyperplasia, and therefore their role in GCA1 is limited. Moreover, in selected cases, significant reduction of hypergastrinemia does not prevent development of ECL carcinoid, suggesting that, in addition to hypergastrinemia, other pathogenic or genetic factors may be involved. Treatment with somatostatin analogues (SSA) might impede ECL-cell hyperplasia by suppressing gastrin secretion and/or by a direct anti-proliferative effect on ECL cells. Treatment with SSAs in GCA1 leads to a substantial tumor load reduction, with a concomitant decrease of serum gastrin levels. Published data indicate an important anti-proliferative effect of SSA on ECL cells, providing clinical benefit and obviating, at least temporarily, the need for invasive therapies for GCA1. Morphometric studies demonstrated that, while antrectomy specifically decreased the volume of ECL cells versus the total volume of endocrine cells, octreotide reduces the overall endocrine cell volume. Although the number of treated patients is small, it has been suggested that SSA may exert important anti-proliferative effects either directly, by inhibiting ECL-cells proliferation, or indirectly through suppression of gastrin hypersecretion.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD Ricardo Caponero
#140 Serotonin expression in gastric neuroendocrine tumors and in foci of endocrine cell hyperplasia
Introduction: The most abundant neuroendocrine (NE) cell population of the human oxyntic mucosa is the enterochromaffin-like (ECL) cells, followed by ghrelin, somatostatin and serotonin cells, respectively. All types of ECL cell carcinoids (ECL-CCs) contain serotonin cells but in a varying frequency. Hitherto, only foci of ECL and ghrelin cell hyperplasia have been described in the peritumorous mucosa of types I and II ECL-CCs. It is established that hypergastrinaemia can cause ECL cell hyperplasia but it does not affect serotonin cells. The vesicular monoamine transporter 2 (VMAT 2) is used as an immunohistochemical marker for ECL cells.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: MD, PhD Apostolos Tsolakis
Authors: Tsolakis A, Falkmer S, Grimelius L, ...